NVDA vs LLY
NVIDIA Corporation vs Eli Lilly and Company · Updated Jun 26, 2026
NVDA — 10 winsLLY — 13 wins
Price Performance
NVDA +26.27%LLY +41.83%
Performance
| NVDA | LLY | |
|---|---|---|
| 1 Month | -9.36% | +6.24% |
| 3 Months | +9.02% | +24.01% |
| 6 Months | +6.02% | +5.08% |
| YTD | +4.42% | +5.25% |
| 1 Year | +31.67% | +45.37% |
| 3 Year | +606.55% | +228.67% |
| 5 Year | +1454.19% | +687.75% |
Yearly Returns
| YTD | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NVDA | +3.6% | +34.8% | +178.8% | +245.9% | -51.5% | +124.3% | +117.7% | +72.4% | -32.9% | +89.8% | +229.9% | +63.7% |
| LLY | +4.4% | +37.4% | +30.4% | +59.7% | +35.1% | +66.9% | +27.7% | +14.4% | +36.7% | +13.2% | -11.3% | +20.3% |
Valuation
| NVDA | LLY | |
|---|---|---|
| P/E Ratio | 39.74 | 40.18 |
| Forward P/E | 12.56 | 24.06 |
| PEG Ratio | 1.20 | 1.77 |
| P/S Ratio | 23.63 | 14.39 |
| P/B Ratio | 32.44 | 33.32 |
| EV/EBITDA | 35.31 | 32.20 |
Financials
| NVDA | LLY | |
|---|---|---|
| EPS (TTM) | $4.90 | $28.15 |
| Gross Margin | +75.00% | +78.98% |
| Operating Margin | +65.02% | +46.44% |
| Net Margin | +63.06% | +37.36% |
| ROE | +76.33% | +81.01% |
| ROA | +58.06% | +21.68% |
| Debt/Equity | 0.07 | 1.39 |
Growth
| NVDA | LLY | |
|---|---|---|
| Revenue Growth YoY | +73.21% | +55.55% |
| Revenue Growth QoQ | +19.51% | +2.63% |
| EPS Growth YoY | +97.75% | +169.94% |
| EPS Growth QoQ | +35.38% | +11.77% |
Technical
| NVDA | LLY | |
|---|---|---|
| RSI (14) | 36.45 | 60.79 |
| % From 20-Day SMA | -6.76% | +1.20% |
| % From 50-Day SMA | -7.37% | +10.35% |
| % From 200-Day SMA | +2.21% | +16.19% |
| % From 52-Week High | -17.67% | -4.36% |
| % From 52-Week Low | +30.47% | +81.33% |
Analyst Ratings
NVDA
Buy(70 analysts)
Strong SellHoldStrong Buy
Price Target
$316.79
+50.73% upside
LLY
Buy(19 analysts)
Strong SellHoldStrong Buy
Price Target
$1271.24
+15.73% upside
Overview
| NVDA | LLY | |
|---|---|---|
| Sector | Technology | Healthcare |
| Industry | Semiconductors | Drug Manufacturers - General |
| Exchange | NASDAQ | NYSE |
| Market Cap | $5.10T | $1.04T |
| Shares Outstanding | 24.22B | 941.7M |
| Avg Volume (10D) | 149.03M | 2.95M |
| Dividend Yield | 0.13% | 0.63% |
Frequently Asked Questions
Is NVDA or LLY a better buy right now?
Based on 23 comparable metrics, LLY leads in 13 categories while NVDA leads in 10. LLY has a consensus analyst rating with 19 analysts covering the stock. Neither stock should be purchased based on a single comparison — consider your investment goals and risk tolerance.
Which stock has better performance, NVDA or LLY?
Over the past year, NVDA returned +31.67% compared to LLY's +45.37%. In the short term (1 month), NVDA returned -9.36% vs LLY's +6.24%.
Is NVDA or LLY more expensive?
NVDA trades at a P/E of 39.74 compared to LLY's 40.18. On a price-to-sales basis, NVDA trades at 23.63x vs LLY's 14.39x. Forward P/E: NVDA at 12.56 vs LLY at 24.06.
Which stock has higher growth, NVDA or LLY?
NVDA's revenue grew +73.21% year-over-year compared to LLY's +55.55%. EPS growth: NVDA at +97.75% vs LLY at +169.94%.
Do NVDA and LLY pay dividends?
NVDA pays a dividend with a yield of 0.13%. LLY pays a dividend with a yield of 0.63%.
Which stock do analysts prefer, NVDA or LLY?
NVDA has 70 analysts with a target price of $316.79 (+50.73% upside). LLY has 19 analysts with a target of $1271.24 (+15.73% upside).
Data updated daily. All comparisons based on latest available market data. Not investment advice.